Sigachi Industries Ltd, a global leader in pharmaceutical excipients and active pharmaceutical ingredients (APIs), announced its financial results for the second quarter of FY26, alongside key updates following the fire at its Pashamylaram facility on 30th June 2025. Following the incident, Sigachi has maintained business continuity by shifting production to its Dahej and Jhagadia units. The company is accelerating both operational and cultural transformation to strengthen long-term resilience and profitability, while keeping execution discipline, stakeholder confidence, and sustainable growth at the forefront.
Significant developments include the fast-tracked expansion of Dahej SEZ, adding 12,000 MTPA of capacity, with civil works already in progress. Once complete, this will bring the total MCC capacity to 30,000 MTPA. Additionally, the Hyderabad API R&D center is now fully operational, consolidating critical API development and analytical work under one roof.
Looking ahead, Sigachi expects a strong second half for FY26, driven by higher capacity utilization and strategic portfolio adjustments. Amit Raj Sinha, MD & CEO, noted, “Q2 FY26 has been a period of careful rebuilding and steady progress. Our teams have worked diligently to maintain seamless operations and support our customers, reinforcing our commitment to resilience, trust, and sustainable growth as we move into the remainder of the year.”
Sigachi Industries Limited operates four manufacturing units across Telangana, Gujarat, and Karnataka. The company also maintains subsidiaries in the UAE and USA to serve overseas clients more effectively. Its product range includes APIs, intermediates, excipients, custom blends, and contract manufacturing services. With over three decades in the sector, Sigachi exports to clients in 65+ countries and maintains a focus on regulatory compliance, technology adoption, and product quality across pharmaceutical, food, and nutrition markets.
